PARIS--(BUSINESS WIRE)--Ipsen (Paris:IPN) today announced that, following shareholder approval of Vernalis plc (LSE:VER), Ipsen has completed its purchase of Apokyn® and Vernalis’ US Commercial Operations. The subscription by Ipsen for 35,253,134 new ordinary shares of £0.05 (5 pence) each in the capital of Vernalis, as part of the Purchase arrangements, has also been completed today.
